Literature DB >> 7783302

Serum total cholesterol and mortality. Confounding factors and risk modification in Japanese-American men.

C Iribarren1, D M Reed, C M Burchfiel, J H Dwyer.   

Abstract

OBJECTIVE: To further investigate the relationship between serum total cholesterol (TC) level and mortality due to major causes. In particular, is the elevated mortality among persons with low TC levels due to confounding conditions that both lower TC level and increase the risk of mortality, and is the association between low or high TC level and mortality homogeneous in the population or, alternatively, restricted to persons with other risk factors? STUDY
DESIGN: Prospective cohort study.
SETTING: Free-living population in Oahu, Hawaii. PARTICIPANTS: A total of 7049 middle-aged men of Japanese ancestry. MAIN OUTCOME MEASURES: Age- and risk factor-adjusted mortality due to coronary heart disease, hemorrhagic stroke, cancer, chronic obstructive pulmonary disease, nonmalignant liver disease, trauma, miscellaneous and unknown, and all causes.
RESULTS: During 23 years of follow-up, a total of 1954 deaths were documented (38% cancer, 25% cardiovascular, and 37% other). Men with low serum TC levels (< 4.66 mmol/L [< 180 mg/dL]) were found to have several adverse health characteristics, including a higher prevalence of current smoking, heavy drinking, and certain gastrointestinal conditions. In an age-adjusted model, and in relation to the reference group (4.66 to 6.19 mmol/L [180 to 239 mg/dL]), those in the lowest TC group (< 4.66 mmol/L [< 180 mg/dL]) were at significantly higher risk of mortality due to hemorrhagic stroke (relative risk [RR], 2.41; 95% confidence interval [Cl], 1.45 to 4.00), cancer (RR, 1.41; 95% Cl, 1.17 to 1.69), and all causes (RR, 1.23; 95% Cl, 1.09 to 1.38). Adjustment for confounders in multivariate analysis (and exclusion of cases with prevalent disease at baseline and deaths through year 5) did not explain the risk of fatal hemorrhagic stroke but reduced the excess risk of cancer mortality by 51% (to 1.20 from 1.41) and reduced the excess risk of all-cause mortality by 56% (to 1.10 from 1.32) in the low TC group. In addition, there were clear differences in the patterns of risk when comparing men with and without selected risk factors (ie, smoking, alcohol consumption, and untreated hypertension).
CONCLUSIONS: We conclude that the excess mortality at low TC levels can be partially explained by confounding with other determinants of death and by preexisting disease at baseline, and TC-mortality associations are not homogeneous in the population. In our study, TC level was not associated with increased cancer or all-cause mortality in the absence of smoking, high alcohol consumption, and hypertension.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7783302

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  15 in total

Review 1.  The relationship between cholesterol and stroke: implications for antihyperlipidaemic therapy in older patients.

Authors:  C Sarti; M Kaarisalo; J Tuomilehto
Journal:  Drugs Aging       Date:  2000-07       Impact factor: 3.923

2.  Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean national health system prospective cohort study.

Authors:  Shah Ebrahim; Joohon Sung; Yun-Mi Song; Robert L Ferrer; Debbie A Lawlor; George Davey Smith
Journal:  BMJ       Date:  2006-06-06

3.  Cholesterol efflux capacity does not associate with coronary calcium, plaque vulnerability, and telomere length in healthy octogenarians.

Authors:  Francesca Zimetti; Wladimir M Freitas; Alessandra M Campos; Mauricio Daher; Maria Pia Adorni; Franco Bernini; Andrei C Sposito; Ilaria Zanotti
Journal:  J Lipid Res       Date:  2018-02-07       Impact factor: 5.922

4.  High plasma levels of oxidatively modified low-density lipoproteins are associated with the suppressed expression of immunomodulatory molecules in patients with hematological malignancies.

Authors:  Hai-Qing Yang; Fa-Qi Qiu; K E Jin; Neng-Gang Jiang; L I Zhang
Journal:  Exp Ther Med       Date:  2015-03-27       Impact factor: 2.447

5.  Relationships of dehydroepiandrosterone sulfate in the elderly with functional, psychological, and mental status, and short-term mortality: a French community-based study.

Authors:  C Berr; S Lafont; B Debuire; J F Dartigues; E E Baulieu
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

6.  Late-life factors associated with healthy aging in older men.

Authors:  Christina L Bell; Randi Chen; Kamal Masaki; Priscilla Yee; Qimei He; John Grove; Timothy Donlon; J David Curb; D Craig Willcox; Leonard W Poon; Bradley J Willcox
Journal:  J Am Geriatr Soc       Date:  2014-04-29       Impact factor: 5.562

7.  A Mendelian randomization analysis of circulating lipid traits and breast cancer risk.

Authors:  Alicia Beeghly-Fadiel; Nikhil K Khankari; Ryan J Delahanty; Xiao-Ou Shu; Yingchang Lu; Marjanka K Schmidt; Manjeet K Bolla; Kyriaki Michailidou; Qin Wang; Joe Dennis; Drakoulis Yannoukakos; Alison M Dunning; Paul D P Pharoah; Georgia Chenevix-Trench; Roger L Milne; David J Hunter; Hall Per; Peter Kraft; Jacques Simard; Douglas F Easton; Wei Zheng
Journal:  Int J Epidemiol       Date:  2020-08-01       Impact factor: 7.196

8.  Characteristics of subjects with very low serum low-density lipoprotein cholesterol and the risk for intracerebral hemorrhage.

Authors:  Jae-Geun Lee; Sung Joo Koh; So Yeon Yoo; Jung Re Yu; Sang Ah Lee; Gwanpyo Koh; Daeho Lee
Journal:  Korean J Intern Med       Date:  2012-09-01       Impact factor: 2.884

9.  Cholesterol lowering to prevent stroke: who, when, and how?

Authors:  Richard A Bernstein
Journal:  Curr Treat Options Neurol       Date:  2006-11       Impact factor: 3.972

10.  Association of serum levels of lipid and its novel constituents with the different stages of esophageal carcinoma.

Authors:  Yutao Diao; Hao Li; Huiqing Li; Yingzhi Zhou; Qing Ma; Yan Wang; Dong Li
Journal:  Lipids Health Dis       Date:  2009-10-29       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.